We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Novel biomarkers for PARP inhibitor trials for children with cancer
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Moving Artificial Intelligence of Functional Imaging for children’s tumours into a multi-centre environment through a Clinical Decision Support System
Unravelling clinical heterogeneity in Philadelphia positive ALL
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
High-risk rhabdomyosarcoma patient derived 3D cultures to screen for novel drugs that enhance sensitivity to standard treatment
Minimal residual disease detection of ependymoma by microRNA biomarker profile evaluation as part of SIOP Ependymoma II trial
